Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 12Unknown 7Recruiting 7Terminated 3Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Genitourinary 7

Conditions

Breast Neoplasms 1789Neoplasms 1516Carcinoma, Non-Small-Cell Lung 1053Prostatic Neoplasms 965Colorectal Neoplasms 889Lung Neoplasms 809Pancreatic Neoplasms 583Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 540Stomach Neoplasms 523Ovarian Neoplasms 513Neoplasm Metastasis 492Multiple Myeloma 491Recurrence 417Melanoma 390Squamous Cell Carcinoma of Head and Neck 374Uterine Cervical Neoplasms 366Brain Neoplasms 364Head and Neck Neoplasms 355Esophageal Neoplasms 320Precursor Cell Lymphoblastic Leukemia-Lymphoma 313Endometrial Neoplasms 311Lymphoma 309Triple Negative Breast Neoplasms 301Glioblastoma 298Rectal Neoplasms 284Urinary Bladder Neoplasms 268Sarcoma 266Hematologic Neoplasms 266Colonic Neoplasms 257

Interventions

testosterone enanthate 1disitamab vedotin 1Radiotherapy 1Metastasectomy 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Recruiting × Castration-resistant Prostate Cancer × Clear all
NCT03522064 2026-04-23

HiTeCH

St Vincent's Hospital, Sydney

Phase 2 Recruiting
30 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT07259213 2026-04-01

RAD402

Radiopharm Theranostics, Ltd

Phase 1/2 Recruiting
73 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06636123 2026-01-27

GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy

Virginia Commonwealth University

Phase 1 Recruiting
30 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06585007 2024-09-05

MEDCARE

Universitaire Ziekenhuizen KU Leuven

Phase 3 Recruiting
246 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06343038 2024-08-14

PROGNOSTICS

University Hospital, Basel, Switzerland

Phase 1 Recruiting
25 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06227156 2024-05-23

Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

RemeGen Co., Ltd.

Phase 2 Recruiting
40 enrolled
Genitourinary

Castration-resistant Prostate Cancer

NCT06321679 2024-03-20

RESPECT

European Institute of Oncology

Recruiting
40 enrolled
Genitourinary

Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡